Telix Reports US$186M Q1 Revenue, Up 62% YOY
Telix announces its Annual General Meeting of shareholders to be held...
Read moreLatest News
Category: ASX
Notice of Annual General Meeting 2025
Telix announces its Annual General Meeting of shareholders to be held...
Read more
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Telix today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1...
Read more
Telix Responds to Recent U.S. Government Actions
Telix advises that it does not expect any material impact on its business or supply chain as the result of the international trade tariffs levied by the U.S. government, announced...
Read more
Anne Whitaker Appointed as Non-Executive Director
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April...
Read more
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
Telixtoday announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide...
Read more
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
Telix today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company’s...
Read more
Telix Completes Acquisition of FAP-targeting Theranostic Candidates
Telix today announces that it has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in...
Read more
Patients Risk Missing Out on Revolution in Cancer Treatment: Report
Tens of thousands of Australians risk missing out on a new era of cancer treatment if Australia fails to fund and build the medical infrastructure needed to support it, according...
Read more
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
Telix invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an...
Read more